Published in Antimicrob Agents Chemother on September 01, 2000
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | NCT00388167
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother (2005) 4.89
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother (2002) 2.76
In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother (2002) 2.67
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother (2002) 2.60
Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother (2005) 2.54
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother (2002) 2.26
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother (2005) 2.08
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother (2005) 2.07
The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell (2003) 2.00
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother (2002) 2.00
Candida infections of the genitourinary tract. Clin Microbiol Rev (2010) 1.90
Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol (2003) 1.89
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis (2008) 1.82
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother (2006) 1.76
Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans. Antimicrob Agents Chemother (2011) 1.45
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother (2006) 1.16
Strategies to prevent, treat, and provoke Corynebacterium-associated hyperkeratosis in athymic nude mice. J Am Assoc Lab Anim Sci (2011) 1.09
Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood (2008) 1.06
Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob Agents Chemother (2004) 1.06
Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother (2006) 0.99
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother (2011) 0.97
Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun (2002) 0.94
Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother (2004) 0.94
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother (2006) 0.93
Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother (2005) 0.90
Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation. Antimicrob Agents Chemother (2003) 0.89
Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2008) 0.87
Stage-specific innate immune recognition of Aspergillus fumigatus and modulation by echinocandin drugs. Med Mycol (2008) 0.85
Central nervous system Aspergillus fumigatus infection after near drowning. J Clin Pathol (2004) 0.84
Caspofungin disk diffusion breakpoints and quality control. J Clin Microbiol (2008) 0.83
Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes. Eur J Clin Microbiol Infect Dis (2004) 0.82
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis (2010) 0.82
What's New in Antifungals? Curr Infect Dis Rep (2003) 0.81
In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. Antimicrob Agents Chemother (2014) 0.81
Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother (2009) 0.80
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother (2017) 0.78
Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother (2002) 0.77
Disparate proteome responses of pathogenic and nonpathogenic aspergilli to human serum measured by activity-based protein profiling (ABPP). Mol Cell Proteomics (2013) 0.76
Micafungin in the treatment of candiduria: A case series. Med Mycol Case Rep (2016) 0.75
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol (1998) 7.01
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother (1994) 6.45
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 5.76
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis (1992) 3.68
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother (1997) 2.76
Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol (1997) 2.58
In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J Med Vet Mycol (1997) 2.50
Resistant fits for some commonly used logistic models with medical application. Biometrics (1982) 2.38
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol (1999) 2.10
Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother (1997) 1.87
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother (1997) 1.83
Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis (1995) 1.47
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother (1998) 1.15
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 5.76
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
Chemiluminescence and superoxide production by myeloperoxidase-deficient leukocytes. J Clin Invest (1976) 3.90
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ (1993) 3.26
Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J Neurosci (1989) 3.24
Bactericidal activity of a superoxide anion-generating system. A model for the polymorphonuclear leukocyte. J Exp Med (1979) 3.19
Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun (1996) 3.08
Artificial 'spin ice' in a geometrically frustrated lattice of nanoscale ferromagnetic islands. Nature (2006) 2.96
Red cell distribution width, haemoglobin A1c and incidence of diabetes mellitus. J Intern Med (2014) 2.85
Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus. J Clin Microbiol (1993) 2.85
Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg (1999) 2.79
Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol (1998) 2.74
comK encodes the competence transcription factor, the key regulatory protein for competence development in Bacillus subtilis. Mol Microbiol (1995) 2.68
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis (1998) 2.61
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother (2002) 2.60
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun (1990) 2.55
Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest (1984) 2.53
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther (2004) 2.42
Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2000) 2.41
Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. J Clin Invest (1991) 2.38
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother (1995) 2.37
Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J (1992) 2.32
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Fibroblast growth factor 2 control of vascular tone. Nat Med (1998) 2.21
In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother (1998) 2.13
Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature (1990) 2.10
Red blood cell distribution width is associated with incidence of atrial fibrillation. J Intern Med (2013) 2.10
Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab (1998) 2.07
Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis (1990) 2.06
Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events. J Immunol (1992) 2.05
Treatment of lymphedema with a multicompartmental pneumatic compression device. J Am Acad Dermatol (1989) 2.04
Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J Antibiot (Tokyo) (1992) 2.02
Antimicrobial activity of myeloperoxidase. Methods Enzymol (1984) 2.02
Formation of singlet oxygen by the myeloperoxidase-mediated antimicrobial system. J Biol Chem (1977) 2.02
Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest (1986) 2.01
A double-blind crossover comparison of topical anesthetics. J Am Dent Assoc (1979) 1.98
Role of iron and ethylenediaminetetraacetic acid in the bactericidal activity of a superoxide anion-generating system. Arch Biochem Biophys (1981) 1.86
Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A (2005) 1.83
The regulation of competence transcription factor synthesis constitutes a critical control point in the regulation of competence in Bacillus subtilis. J Bacteriol (1994) 1.82
Localisation of haematuria by red cell analysers and phase contrast microscopy. Nephron (1989) 1.81
Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother (1997) 1.80
Abortion in America. Am J Psychiatry (1970) 1.80
Comparative features and course of ulcerative and granulomatous colitis. N Engl J Med (1970) 1.74
Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci U S A (1994) 1.73
Differential inactivation of Escherichia coli membrane dehydrogenases by a myeloperoxidase-mediated antimicrobial system. Biochemistry (1990) 1.72
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (2000) 1.66
Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med (1991) 1.66
Ethylene formation by polymorphonuclear leukocytes. Role of myeloperoxidase. J Exp Med (1978) 1.64
Absence of monoclonal-antibody-defined protein complex in boy with abnormal leucocyte function. Lancet (1984) 1.63
The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem (1987) 1.61
In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother (1999) 1.57
SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol (1995) 1.57
Role of CD8 T cells in primary Chlamydia infection. Infect Immun (1995) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Hydroxyl radical generation by polymorphonuclear leukocytes measured by electron spin resonance spectroscopy. J Clin Invest (1979) 1.56
Autonomous replication in human cells of multimers of specific human and bacterial DNA sequences. Mol Cell Biol (1993) 1.54
Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide. Arch Biochem Biophys (1998) 1.54
Characterization and species distribution of high affinity GTP-coupled receptors for human rantes and monocyte chemoattractant protein 1. J Exp Med (1993) 1.52
Effect of acetylsalicylic acid on lysosomes. Proc Soc Exp Biol Med (1966) 1.52
Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol (1999) 1.51
Hemorrhagic colitis with Escherichia coli O157:H7 preceding adult hemolytic uremic syndrome. Arch Intern Med (1985) 1.48
A philosophy of limb salvage in war: use of the fixateur externe. Mil Med (1991) 1.47
Ceruloplasmin and atrial fibrillation: evidence of causality from a population-based Mendelian randomization study. J Intern Med (2013) 1.47
A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. J Clin Invest (1989) 1.47
Erythema ab igne: a histopathological study. J Invest Dermatol (1966) 1.46
Use of a temporary screw for alignment and fixation of sagittal mandibular condylar fractures with lateral screws. Int J Oral Maxillofac Surg (2010) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Butorphanol and nalbuphine: a pharmacologic comparison. Oral Surg Oral Med Oral Pathol (1985) 1.43
Common genetic variation near the connexin-43 gene is associated with resting heart rate in African Americans: a genome-wide association study of 13,372 participants. Heart Rhythm (2012) 1.43
Late administration of monoclonal antibody to leukocyte function-antigen 1 abrogates incipient murine cerebral malaria. Eur J Immunol (1991) 1.42
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest (1996) 1.42
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Aust (1997) 1.40
ERCP and balloon dilation is a valuable alternative to surgical biliodigestive anastomosis in the long common channel syndrome in childhood. Endoscopy (1995) 1.40
Translational control: recognition of the methylated 5' end and an internal sequence in eukaryotic mRNA by the initiation factor that binds methionyl-tRNAfMet. Proc Natl Acad Sci U S A (1978) 1.39
A comparative study of the skeletal morphology of the temporo-mandibular joint of children and adults. J Postgrad Med (2008) 1.39
Development of C5a receptor antagonists. Differential loss of functional responses. J Immunol (1994) 1.39
T-lymphocyte subsets in acute illness. Crit Care Med (1995) 1.39
Postoperative radiotherapy for Dukes' B and C rectal cancer: Peter MacCallum Cancer Institute experience. Australas Radiol (1996) 1.38